How Should Concurrent Arterial and Venous Thrombosis Associated With SARS-CoV-2 Infection Be Managed

  • Athina Dimosiari Department of Emergency Medicine, General Hospital of Kozani, Kozani, Greece
  • Dimitrios Patoulias Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, General Hospital “Hippokration”, Thessaloniki, Greece
  • Theodoros Michailidis Second Department of Internal Medicine, Aristotle University of Thessaloniki, General Hospital “Hippokration”, Thessaloniki, Greece
  • Theodoros Dimitroulas Fourth Department of Internal Medicine, Aristotle University of Thessaloniki, General Hospital “Hippokration”, Thessaloniki, Greece

Keywords

COVID-19, renal artery thrombosis, pulmonary embolism

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), is associated with a high incidence of thrombotic complications involving both the arterial and the venous systems. However, concurrent arterial and venous thrombosis is extremely rare. Herein, we present the case of a 75-year-old male patient with severe COVID-19 who developed bilateral renal artery thrombosis and pulmonary embolism during the disease course. To our knowledge, this is the first such case described in the literature.

VIEW THE ENTIRE ARTICLE

References

  • Leentjens J, van Haaps TF, Wessels PF, Schutgens REG, Middeldorp S. COVID-19-associated coagulopathy and antithrombotic agents-lessons after 1 year. Lancet Haematol 2021 Jul;8(7):e524–e533.
  • Perico L, Benigni A, Casiraghi F, Ng LFP, Renia L, Remuzzi G. Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. Nat Rev Nephrol 2021 Jan;17(1):46–64.
  • Del Castillo-García S, Minguito-Carazo C, Echarte JC, Rodríguez-Santamarta M, González TB, Terroba Seara S, et al. A case report of arterial and venous thromboembolism in a patient with severe COVID-19 pneumonia. Eur Heart J Case Rep 2020 Nov 17;4(6):1–6.
  • Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020 Apr;18(4):844–847.
  • Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers D, Kant KM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res 2020 Jul;191:148–150.
  • Rizk JG, Gupta A, Lazo JG Jr, Sardar P, Henry BM, Lavie CJ, et al. To anticoagulate or not to anticoagulate in COVID-19: lessons after 2 years. Semin Thromb Hemost 2022 Apr 25. doi: 10.1055/s-0042-1744302. Epub ahead of print.
  • Farkouh ME, Stone GW, Lala A, Bagiella E, Moreno PR, Nadkarni GN, et al. Anticoagulation in patients with COVID-19: JACC Review Topic of the Week. J Am Coll Cardiol 2022 Mar 8;79(9):917–928.
  • Li G, Lip GYH, Holbrook A, Chang Y, Larsen TB, Sun X, et al. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies. Eur J Epidemiol 2019 Feb;34(2):173–190.
  • Published: 2022-05-17

    Issue: 2022: Vol 9 No 5 (view)

    Section: Articles

    How to cite:
    1.
    Dimosiari A, Patoulias D, Michailidis T, Dimitroulas T. How Should Concurrent Arterial and Venous Thrombosis Associated With SARS-CoV-2 Infection Be Managed. EJCRIM 2022;9 doi:10.12890/2022_003366.